Models of Sepsis: Subacute Peritonitis in Sheep and Rats

  • C. M. Martin
  • A. Neal
  • W. J. Sibbald

Abstract

To avoid incorrect conclusions research should be designed and conducted with careful attention to datails and underlying assumptions. The study of sepsis and multiple organ failure challenges the investigator since the pathogenesis of these syndromes is extremely complicated and they present with a myriad of manifestations. Therefore, studies of these two processes should be designed to address discrete questions.

Keywords

Placebo Permeability Surfactant Starch Dopamine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bochner BS, Luscinskas FW, Gimbrone MA Jr, Newman W, Sterbinsky SA, Derse-Anthony CP, Klunk D, Schleimer RP (1991) Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules. J Exp Med 173:1553–1557.PubMedCrossRefGoogle Scholar
  2. 2.
    Gnidec AG, Sibbald WJ, Cheung H, Metz C (1988) Ibuprofen reduces the progression of permeability edema in an animal model of hyperdynamic sepsis. J Appl Physiol 65:1024–1032.PubMedGoogle Scholar
  3. 3.
    Wichterman KA, Baue AE, Chaudry IH (1980) Sepsis and septic shock — a review of laboratory models and a proposal. J Surg Res 29:189–201.PubMedCrossRefGoogle Scholar
  4. 4.
    Fink MP, Heard SO (1990) Laboratory models of sepsis and septic shock. J Surg Res 49:186–196.PubMedCrossRefGoogle Scholar
  5. 5.
    Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RMH, Sibbald WJ (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 101:1644–1655.PubMedCrossRefGoogle Scholar
  6. 6.
    Benjamin E, Leibowitz AB, Oropello J, Iberti TJ (1992) Systemic hypoxic and inflammatory syndrome: an alternative designation for “sepsis syndrome”. Crit Care Med 20:680–682.PubMedCrossRefGoogle Scholar
  7. 7.
    Pinsky MR, Matuschak GG (1989) Multiple systems organ failure: failure of host defense homeostasis. Crit Care Clin 5:199–220.PubMedGoogle Scholar
  8. 8.
    Bersten A, Sibbald WJ (1992) Circulatory disturbances in multiple systems organ failure. Crit Care Clin 5:233–254.Google Scholar
  9. 9.
    Ziegler EJ, Fischer CJ Jr, Sprung CL, Straube RC, Sadoff JC, Foulke GE, Wortel CH, Fink MP, Dellinger RP, Teng NNH, Allen IE, Berger HJ, Knatterud GL, LoBuglio AF, Smith CR (1991) Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. N Engl J Med 324:429–436.PubMedCrossRefGoogle Scholar
  10. 10.
    Greenman RL, Schein RMH, Martin MA, Wenzel RP, MacIntyre NR, Emmanuel G, Chmel H, Kohler RB, McCarthy M, Plouffe J, Russell JA (1991) A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 266:1097–1102.PubMedCrossRefGoogle Scholar
  11. 11.
    Parker MM, Parrillo JE (1990) Myocardial function in septic shock. J Crit Care 5(1):47–61.CrossRefGoogle Scholar
  12. 12.
    Fish RE, Burns AH, Lang CH, Spitzer JA (1985) Myocardial dysfunction in a nonlethal, nonshock model of chronic endotoxemia. Circ Shock 16: 241–252.PubMedGoogle Scholar
  13. 13.
    Curtis SE, Cain SM (1992) Regional and systemic oxygen delivery/uptake relations and lactate flux in hyperdynamic, endotoxin-treated dogs. Am Rev Respir Dis 145:348–354.PubMedGoogle Scholar
  14. 14.
    Lang CH, Bagby GJ, Ferguson JL, Spitzer JJ (1984) Cardiac output and redistribution of organ blood flow in hypermetabolic sepsis. Am J Physiol 246:R331–R337.PubMedGoogle Scholar
  15. 15.
    Bersten AD, Hersch M, Cheung H, Rutledge FS, Sibbald WJ (1992) The effect of various sympathomimetics on the regional circulations in hyperdynamic sepsis. Surgery 112:549–561.PubMedGoogle Scholar
  16. 16.
    Hartl WH, Gunther B, Inthorn D (1988) Reactive hyperemia in patients with septic conditions. Surgery 103:440–444.PubMedGoogle Scholar
  17. 17.
    Stahl TJ, Alden PB, Ring WS, Madoff RC, Cerra FB (1990) Sepsis-induced diastolic dysfunction in chronic canine peritonitis. Am J Physiol 258:H625–H633.PubMedGoogle Scholar
  18. 18.
    Fox G, Lam C, Darrah WC, Neal A, Rutledge FS, Sibbald WJ (1991) The metabolic regulation of right ventricular blood flows is not immediate in sepsis. Clin Invest Med 14:A16.Google Scholar
  19. 19.
    Craig I, Judges D, Gnidec A, Lefcoe M, Paterson N, Finley R, Sibbald W (1987) Pulmonary permeability edema in a large animal model of nonpulmonary sepsis. A morphologic study. Am J Pathol 128: 241–251.PubMedGoogle Scholar
  20. 20.
    Hersch M, Gnidec AA, Bersten AD (1990) Histologic and ultrastructural changes in nonpulmonary organs during early hyperdynamic sepsis. Surgery 107: 397–410.PubMedGoogle Scholar
  21. 21.
    Hersch M, Bersten A, Rutledge F, Troster M, Groom A, Sibbald W (1989) Quantitative evidence of microcirculatory compromise in skeletal muscle of normotensive hyperdynamic septic sheep. Crit Care Med 17:S60.Google Scholar
  22. 22.
    Ertel W, Morrison M, Wang P, Zheng F, Ayala A, Chaudry I (1991) The complex pattern of cytokines in sepsis. Ann Surg 214:141–148.PubMedCrossRefGoogle Scholar
  23. 23.
    Sibbald WJ, Campbell D, Raper R, Rutledge F, Cheung H (1989) The effects of prostaglandin E1 on lung injury complicating hyperdynamic sepsis in sheep. Am Rev Respir Dis 139:674–681.PubMedGoogle Scholar
  24. 24.
    Gnidec AG, Finley R, Sibbald WJ (1988) Effect on dobutamine on lung microvascular fluid flux in sheep with sepsis syndrome. Chest 93:180–186.PubMedCrossRefGoogle Scholar
  25. 25.
    Morisaki H, Bloos F, Neal A, Pitt M, Cross L, Keys J, Martin C, Sibbald W (1992) Colloid infusion preserves microvascular integrity better than crystalloid in hyperdynamic sepsis. Crit Care Med 20:S101.Google Scholar
  26. 26.
    Martin CM, Yaghi A, McCormack D, Sibbald WJ, Paterson NAM (1991) Selective impairment of regional vascular responsiveness in a rat model of hyperdynamic sepsis. Am Rev Respir Dis 143:A86 (abstract).Google Scholar
  27. 27.
    Fox G, Paterson N, McCormack DG (1992) Attenuated hypoxic pulmonary vasoconstriction in vivo in a rat model of hyperdynamic sepsis. Am Rev Respir Dis 145:A629.Google Scholar
  28. 28.
    Martin CM, Cross L, Sibbald WJ (1992) Modulation of organ blood flow by endothelium-derived relaxant factor is not altered in sepsis. Am Rev Respir Dis 145:A312.Google Scholar
  29. 29.
    Gray G, Schott C, Julou-Schaeffer G, Fleming I, Parratt J, Stoclet J (1991) The effect of inhibitors of the L-arginine/nitric oxide pathway on endotoxin-induced loss of vascular responsiveness in anaesthetized rats. Br J Pharmacol 103:1218–1224.PubMedGoogle Scholar
  30. 30.
    Nelson DP, Samsel RW, Wood LDH, Schumacker PT (1988) Pathological supply dependence of systemic and intestinal O2 uptake during endotoxemia. J Appl Physiol 64(6):2410–2419.PubMedGoogle Scholar
  31. 31.
    Bloos F, Morisaki H, Neal A, Pitt M, Martin C, Ellis C, Sibbald W (1992) Is the circulatory “reserve” supporting tissue O2 availability depressed in normotensive, hyperdynamic sepsis? Crit Care Med 20:S55.Google Scholar
  32. 32.
    Astiz M, Rackow EC, Weil MH, Schumer W (1988) Early impairment of oxidative metabolism and energy production in severe sepsis. Circ Shock 26: 311–320.PubMedGoogle Scholar
  33. 33.
    Lam C, Tyml K, Martin CM, Sibbald WJ (1991) The skeletal muscle microcirculation in sepsis. Proceedings of the 5th world congress for microcirculation, Louisville, 31 Aug–5 Sept.Google Scholar
  34. 34.
    Ciancio MJ, Hunt J, Jones SB, Filkins JP (1991) Comparative and interactive in vivo effects of tumor necrosis factor alpha and endotoxin. Circ Shock 33:108–120.PubMedGoogle Scholar
  35. 35.
    Dinarello CA (1991) The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome. J Infect Dis 163:1177–1184.PubMedCrossRefGoogle Scholar
  36. 36.
    Sheppard BC, Fraker DL, Norton JA (1989) Prevention and treatment of endotoxin and sepsis lethality with recombinant human tumor necrosis factor. Surgery 106:156–162.PubMedGoogle Scholar
  37. 37.
    Echtenacher B, Falk W, Mannel DN, Krammer PH (1990) Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol 145:3762–3766.PubMedGoogle Scholar
  38. 38.
    Eichacker PQ, Farese A, Hoffman WD, Banks SM, Mouginis T, Richmond S, Kuo GC, MacVittie TJ, Natanson C (1992) Leukocyte CD11b/18 antigen-directed monoclonal antibody improves early survival and decreases hypoxemia in dogs challenged with tumor necrosis factor. Am Rev Respir Dis 145: 1023–1029.PubMedCrossRefGoogle Scholar
  39. 39.
    Eichacker P, MacVittie T, Farese A, Waisman Y, Banks S, Hoffman W, Danner R, Rothlein R, Richmond S, Wison L, Natanson C (1992) Antibody against leukocyte CD 18 membrane protein does not improve outcome in a canine model of human sepsis. Crit Care Med 20:S51 (abstract).CrossRefGoogle Scholar
  40. 40.
    Harada H, Ishizaka A, Yonemaru M, Mallick AA, Hatherill JR, Zheng H, Lilly CM, O’Hanley PT, Raffin TA (1989) The effects of aminophylline and pentoxifylline on multiple organ damage after Escherichia coli sepsis. Am Rev Respir Dis 140(4):974–980.PubMedGoogle Scholar
  41. 41.
    Flamand FJ, Sibbald WJ, Girotti MJ, Martin CM (1992) Pentoxifylline does not protect vascular integrity in sepsis. Crit Care Med 20:S53 (abstract).Google Scholar
  42. 42.
    Evans GF, Snyder YM, Butler LD, Zuckerman SH (1989) Differential expression of interleukin-1 and tumor necrosis factor in murine septic shock models. Circ Shock 29:279–290.PubMedGoogle Scholar
  43. 43.
    Damas P, Reuter A, Gysen P, Demonty J, Lamy M, Franchimont P (1989) Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med 17:975–978.PubMedCrossRefGoogle Scholar
  44. 44.
    Calandra T, Gerain J, Heumann D, Baumgartner JD, Glauser MP (1991) High circulating levels of inter-leukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study Group. Am J Med 91:23–29.PubMedCrossRefGoogle Scholar
  45. 45.
    Debets JM, Kampmeijer R, van der Linden M, van der Linden C, Buurman W (1989) Plasma tumor necrosis factor and mortality in critically ill septic patients. Crit Care Med 17:489–494.PubMedCrossRefGoogle Scholar
  46. 46.
    Hansbrough JF, Zapata-Sirvent RL, Bartle EJ, Anderson JK, Elliott L, Mansour MS, Carter WH (1985) Alterations in splenic lymphocyte subpopulations and increased mortality from sepsis following anesthesia in mice. Anesthesiology 63:267–273.PubMedCrossRefGoogle Scholar
  47. 47.
    Martin CM, MacKinnon T, Lam C, Sibbald WJ (1991) Minimum alveolar concentration (MAC100) and hemodynamic effects of isoflurane in septic rats. Clin Invest Med 14:A24 (abstract).Google Scholar
  48. 48.
    Chaudry IH, Wichterman KA, Baue AE (1979) Effect of sepsis on tissue adenine nucleotide levels. Surgery 85:205.PubMedGoogle Scholar
  49. 49.
    Cumming AD, Driedger AA, McDonald JWD, Lindsay RM, Solez K, Linton AL (1988) Vasoactive hormones in the renal response to systemic sepsis. Am J Kidney Dis 11:23–32.PubMedGoogle Scholar
  50. 50.
    Mori E, Hasebe M, Kobayashi K (1988) Effect of fluid infusion on alterations in metabolite levels in carbohydrate and protein metabolism of septic rats. J Clin Biochem Nutr 5:241–254.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • C. M. Martin
    • 1
  • A. Neal
    • 1
  • W. J. Sibbald
    • 1
  1. 1.A. C. Burton Vascular Biology Laboratory, Victoria Hospital Research InstituteUniversity of Western OntarioLondonCanada

Personalised recommendations